Sarilumab - Regeneron/Sanofi

Drug Profile

Sarilumab - Regeneron/Sanofi

Alternative Names: Anti-IL 6 receptor antibody; Anti-interleukin 6 receptor antibody; Kevzara; REGN-88; SAR-153191

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Regeneron Pharmaceuticals; Sanofi
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • Phase II Juvenile rheumatoid arthritis; Uveitis
  • Discontinued Ankylosing spondylitis

Most Recent Events

  • 12 Dec 2017 Sanofi and Asahi Kasei Pharma agree to co-promote sarilumab in Japan for Rheumatoid arthritis
  • 12 Dec 2017 Launched for Rheumatoid arthritis (Adjunctive treatment) in European Union (SC), before December 2017
  • 12 Dec 2017 Launched for Rheumatoid arthritis (Combination therapy, Second-line therapy or greater) in USA (SC), before December 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top